Vimarsana
Biggest News Aggregation in the World

Page 14 - Accessed August News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accessed August. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accessed August Today - Breaking & Trending Today

Producing Renewable Energy with Osmotic Power - Vimarsana News

Producing Renewable Energy with Osmotic Power

Osmotic power is a form of renewable energy that experts have predicted could have the potential to produce half of Europe’s power by 2030. French energy supplier Sweetch is exploring new ways of producing renewable energy via osmotic power to address carbon emissions associated with our reliance on non-renewable fossil fuels.

Preserving Patient Access to Compounded Medications Act of 2017 - Vimarsana News

Preserving Patient Access to Compounded Medications Act of 2017

The act would have permitted health care facilities to stock up on compounded medications without forcing the supplying 503A pharmacies to register as outsourcing facilities.

Novartis : Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer -September 14, 2023 at 01:26 pm EDT - Vimarsana News

Novartis : Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer -September 14, 2023 at 01:26 pm EDT

Breast Cancer. NCCN Guidelines. Published March 2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf/ Accessed August 2023. European Society...

TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial - Vimarsana News

TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial

Combination reduced the risk of disease progression by 38% versus TAGRISSO monotherapy, the current 1st-line global standard of care ...

ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial - Vimarsana News

ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial

Daiichi Sankyo and AstraZeneca’s ENHERTU showed objective response rates of 49% and 56% with 5.4 mg/kg and 6.4 mg/kg doses, respectively, in primary analysis ENHERTU provided a median...